Neural Therapeutics (FRA:M6B) Ending Cash Position: €0.04 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics Ending Cash Position?

Neural Therapeutics FRA:M6B Ending Cash Position is €0.04 Mil as of Jan. 2026. The stock has 1 warning sign investors should review.

Neural Therapeutics's Ending Cash Position for the quarter that ended in Jan. 2026 was €0.04 Mil.

Neural Therapeutics's quarterly Ending Cash Position declined from Jul. 2025 (€0.10 Mil) to Oct. 2025 (€0.07 Mil) and declined from Oct. 2025 (€0.07 Mil) to Jan. 2026 (€0.04 Mil).

Neural Therapeutics's annual Ending Cash Position declined from Jul. 2023 (€0.19 Mil) to Jul. 2024 (€0.05 Mil) but then increased from Jul. 2024 (€0.05 Mil) to Jul. 2025 (€0.10 Mil).

Neural Therapeutics Ending Cash Position Related Terms

Neural Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics Ending Cash Position Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Ending Cash Position
Get a 7-Day Free Trial 0.00 0.28 0.19 0.05 0.10

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.16 0.10 0.07 0.04

Neural Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neural Therapeutics's Ending Cash Position for the fiscal year that ended in Jul. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.041+0.062
=0.10

Neural Therapeutics's Ending Cash Position for the quarter that ended in Jan. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.071+-0.032
=0.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.04 Mil mean?
Neural Therapeutics (FRA:M6B) has a Ending Cash Position of €0.04 Mil as of Jan. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neural Therapeutics and its competitors.
Is Neural Therapeutics' Ending Cash Position too high?
Neural Therapeutics' current Ending Cash Position is €0.04 Mil.
How does Neural Therapeutics' Ending Cash Position compare to VRTX and REGN?
Neural Therapeutics' Ending Cash Position of €0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neural Therapeutics and its competitors. Neural Therapeutics's current Ending Cash Position is €0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (FRA:M6B) has a current Ending Cash Position of €0.04 Mil. The current Ending Cash Position is €0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Neural Therapeutics (FRA:M6B), the current Ending Cash Position is €0.04 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges NURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.